Apremilast approval expanded to include plaque psoriasis

The oral phosphodiesterase-4 inhibitor apremilast is now indicated for the treatment of moderate to severe plaque psoriasis. On Sept. 23, the manufacturer, Celgene, announced that the Food and Drug...

Field of Interest: Dermatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.